Success Metrics

Clinical Success Rate
100.0%

Based on 1 completed trials

Completion Rate
100%(1/1)
Active Trials
0(0%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_1
2
50%
Ph phase_2
1
25%
Ph phase_3
1
25%

Phase Distribution

2

Early Stage

1

Mid Stage

1

Late Stage

Phase Distribution4 total trials
Phase 1Safety & dosage
2(50.0%)
Phase 2Efficacy & side effects
1(25.0%)
Phase 3Large-scale testing
1(25.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

1 of 1 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

4

all time

Status Distribution
Completed(1)
Other(3)

Detailed Status

unknown3
Completed1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
0
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 12 (50.0%)
Phase 21 (25.0%)
Phase 31 (25.0%)

Trials by Status

completed125%
unknown375%

Recent Activity

0 active trials
Showing 4 of 4
completedphase_1

Recombinant New Coronavirus Vaccine (CHO Cells) to Prevent SARS-CoV-2（COVID-19） Phase I Clinical Trial (3~17 Years Old)

NCT04961359
unknownphase_3

A Phase III Clinical Trial to Determine the Safety and Efficacy of ZF2001 for Prevention of COVID-19

NCT04646590
unknownphase_2

Clinical Study of Recombinant Novel Coronavirus Vaccine

NCT04466085
unknownphase_1

Phase I Clinical Study of Recombinant Novel Coronavirus Vaccine

NCT04445194

Clinical Trials (4)

Showing 4 of 4 trials
NCT04961359Phase 1

Recombinant New Coronavirus Vaccine (CHO Cells) to Prevent SARS-CoV-2（COVID-19） Phase I Clinical Trial (3~17 Years Old)

Completed
NCT04646590Phase 3

A Phase III Clinical Trial to Determine the Safety and Efficacy of ZF2001 for Prevention of COVID-19

Unknown
NCT04466085Phase 2

Clinical Study of Recombinant Novel Coronavirus Vaccine

Unknown
NCT04445194Phase 1

Phase I Clinical Study of Recombinant Novel Coronavirus Vaccine

Unknown

All 4 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
4